Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price

Tyra Biosciences (NASDAQ:TYRA) had its price target lifted by analysts at Piper Sandler from $42.00 to $56.00 in a report released on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective suggests a potential upside of 44.79% from the stock’s previous close.

Several other equities analysts also recently commented on TYRA. Wall Street Zen downgraded Tyra Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. Wedbush boosted their price objective on shares of Tyra Biosciences from $37.00 to $53.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. HC Wainwright upped their price objective on shares of Tyra Biosciences from $30.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. William Blair started coverage on shares of Tyra Biosciences in a report on Tuesday, February 10th. They issued an “outperform” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.67.

Tyra Biosciences Trading Up 1.3%

Tyra Biosciences stock traded up $0.50 during mid-day trading on Friday, hitting $38.68. 199,583 shares of the company’s stock were exchanged, compared to its average volume of 928,282. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $39.15. The stock has a 50 day moving average of $31.95 and a two-hundred day moving average of $22.66. The stock has a market cap of $2.08 billion, a P/E ratio of -19.18 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). As a group, research analysts predict that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. HighVista Strategies LLC increased its position in Tyra Biosciences by 163.6% during the third quarter. HighVista Strategies LLC now owns 65,812 shares of the company’s stock worth $921,000 after acquiring an additional 40,850 shares during the period. Commodore Capital LP raised its stake in Tyra Biosciences by 8.9% during the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after purchasing an additional 275,000 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Tyra Biosciences in the 3rd quarter valued at $2,612,000. Dynamic Technology Lab Private Ltd bought a new stake in Tyra Biosciences in the 2nd quarter valued at $326,000. Finally, Sio Capital Management LLC grew its position in Tyra Biosciences by 94.5% in the 2nd quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock worth $7,754,000 after purchasing an additional 393,657 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.